非清髓性HLA相合同胞供者移植治疗镰状细胞病的三中心结局
三项独立中心共122例成人镰状细胞病患者接受非清髓性HLA相合同胞供者造血祖细胞移植,方案为300 cGy全身照射、阿仑单抗、未处理非格司亭动员外周血HPC及西罗莫司。中位随访4年,1年和5年总生存率分别为93%和85%,无临床显著GVHD,器官功能稳定。
要点
- 该非清髓方案在成人SCD中高效且耐受性好,即使移植前器官功能受损。
- 1年和5年总生存率分别为93%和85%,无慢性GVHD发生。
- 83%植入患者已停用免疫抑制,中位用药489天。
核心结论
- 该非清髓性MRD-HPCT方案在成人SCD中高效、耐受性好,无临床显著GVHD。
研究设计与样本
- 多中心回顾性研究,共122例SCD患者接受非清髓性HLA相合同胞供者HPCT。
- 预处理为300 cGy TBI、阿仑单抗、未处理非格司亭动员外周血HPC及西罗莫司。
- 中位随访4年,移植时中位年龄29岁。
主要发现
- 中性粒细胞和血小板植入中位时间分别为第22天和第19天,41例无需血小板输注。
- 1年和5年总生存率分别为93%和85%。
- 移植后1年和5年供者髓系嵌合率分别为84%和88%,CD3嵌合率分别为48%和53%。
- 2例发生1级和2级皮肤GVHD,无慢性GVHD。
- 83%植入患者已停用免疫抑制,中位用药489天。
关键数值与推荐
- 移植后血红蛋白、溶血指标及肝脏铁水平改善。
- 肺功能、肝脏组织学及神经血管影像保持稳定,提示镰状相关损伤停止进展。
临床怎么用
- 该方案可用于成人SCD患者,包括移植前器官功能受损者。
- 移植后需监测嵌合状态及免疫抑制减停,中位489天可停药。
局限性
- 原文未报告移植失败与植入患者间年龄、性别、移植前镰状并发症、铁蛋白及输注HPC数量的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-myeloablative haematopoietic progenitor cell transplantation (HPCT) from matched related donors (MRD) has been increasingly utilized in sickle cell disease (SCD). A total of 122 patients received 300 cGy of total body irradiation (TBI), alemtuzumab, unmanipulated filgrastim-mobilized peripheral blood HPC and sirolimus. The median follow-up was four years; median age at HPCT was 29 years. Median neutrophil and platelet engraftment occurred on day 22 and 19 respectively; 41 patients required no platelet transfusions. Overall and sickle-free survival at one and five years were 93% and 85% respectively. Age, sex, pre-HPCT sickle complications, ferritin and infused HPC numbers were similar between graft failure and engrafted patients. Mean donor myeloid chimaerism at one and five years post HPCT were 84% and 88%, and CD3 was 48% and 53% respectively. Two patients developed grade 1 and 2 skin graft-versus-host disease (GVHD) with no chronic GVHD. Median days of recipients taking immunosuppression were 489; 83% of engrafted patients have discontinued immunosuppression. Haemoglobin, haemolytic parameters and hepatic iron levels improved post HPCT. Pulmonary function testing, hepatic histology and neurovascular imaging remained stable, suggesting cessation of further sickle-related injury. Fourteen patients had children. In this largest group of adult SCD patients, this regimen was highly efficacious, well-tolerated despite compromised organ functions pre HPCT, and without clinically significant GVHD.
引用
- Alzahrani M, Damlaj M, Jeffries N, et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol. 2021. PMID: 33534948. doi:10.1111/bjh.17311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。